Suppr超能文献

一种BIRC5 COD1癌症组织表型表明转移性乳腺癌患者预后较差。

A BIRC5 COD1 Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients.

作者信息

Bai Yujie, Yuan Feng, Yu Jing, Si Yibei, Zheng Yiwen, Li Dongqing

机构信息

Department of Microbiology, School of Basic Medical of Science, Wuhan University, Wuhan, China.

Department of Scientific Research and Education, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

出版信息

Cancer Inform. 2022 Jun 14;21:11769351221096655. doi: 10.1177/11769351221096655. eCollection 2022.

Abstract

Extensive data research is helpful to find sensitive biomarkers for prognostic prediction of metastatic breast cancer. Through analyzing multiple GEO datasets, literature retrieval, and verified in GEPIA datasets, we identify BIRC5 (Baculoviral IAP repeat containing 5) and CDO1 (Cysteine dioxygenase type 1) as DEGs (differentially expressed genes) between breast tumor and normal tissue and DEGs between metastatic breast cancer and breast cancer in situ. Then, we performed a series of in silico studies on BIRC5 and CDO1 using online tools including the UALCAN, TIMER, TCGA-BRCA, LinkedOmics Kaplan-Meier Plotter, and an R script for analysis. To verify the association of 2 genes expression and patients' clinical data, we detected BIRC5 and CDO1 mRNA in the tissue of 48 breast cancer patients. The results showed the tumor with BIRC5 CDO1 expression generally indicated patients' shorter overall (OS) and relapse-free survival (RFS). Specifically, BIRC5 and CDO1 levels significantly affect OS or RFS in patients with Lymph node metastasis and molecular subtypes of TNBC (triple-negative breast cancer) and Luminal A. A BIRC5 tumor displayed a purer tumor purity and expressed more KIR receptors on NK cells while activating more FOXP3CD25 Treg cells. The CDO1 tumors infiltrated with more immunocytes leading to less tumor purity. In our verified experiment, BIRC5 mRNA level in patients with stage III and over was significantly higher than in patients with stage 0 to II, but there were no significant differences among molecular subtyping groups; TNBC tissue expressed lower CDO1 mRNA level than HER2 and Luminal type cancer tissue. In conclusion, a BIRC5 CDO1 expression type in breast cancer tissue indicates a poorer prognosis of patients. The potential mechanism might be increased BIRC5 expression in cancer tissue is likely to accompany NK cells inhibition, activating more Treg cells, and lacking effective CD8 T cells proliferation. Meanwhile, CDO1 level is positively related to more immunocytes infiltration.

摘要

广泛的数据研究有助于找到用于转移性乳腺癌预后预测的敏感生物标志物。通过分析多个基因表达综合数据库(GEO)数据集、文献检索并在GEPIA数据集中进行验证,我们确定了BIRC5(含杆状病毒IAP重复序列5)和CDO1(1型半胱氨酸双加氧酶)作为乳腺肿瘤与正常组织之间以及转移性乳腺癌与原位乳腺癌之间的差异表达基因(DEG)。然后,我们使用包括UALCAN、TIMER、TCGA - BRCA、LinkedOmics Kaplan - Meier Plotter等在线工具以及一个用于分析的R脚本对BIRC5和CDO1进行了一系列的生物信息学研究。为了验证这两个基因表达与患者临床数据的关联,我们检测了48例乳腺癌患者组织中的BIRC5和CDO1 mRNA。结果显示,具有BIRC5 CDO1表达的肿瘤通常表明患者的总生存期(OS)和无复发生存期(RFS)较短。具体而言,BIRC5和CDO1水平显著影响有淋巴结转移的患者以及三阴性乳腺癌(TNBC)和Luminal A分子亚型患者的OS或RFS。具有BIRC5的肿瘤显示出更高的肿瘤纯度,在自然杀伤(NK)细胞上表达更多的杀伤细胞免疫球蛋白样受体(KIR),同时激活更多的FOXP3 + CD25 +调节性T细胞(Treg)。CDO1肿瘤浸润了更多的免疫细胞,导致肿瘤纯度降低。在我们的验证实验中,III期及以上患者的BIRC5 mRNA水平显著高于0至II期患者,但分子亚型组之间无显著差异;TNBC组织表达的CDO1 mRNA水平低于人表皮生长因子受体2(HER2)和Luminal型癌组织。总之,乳腺癌组织中的BIRC5 CDO1表达类型表明患者预后较差。潜在机制可能是癌组织中BIRC5表达增加可能伴随着NK细胞抑制,激活更多Treg细胞,且缺乏有效的细胞毒性T淋巴细胞(CD8 + T细胞)增殖。同时,CDO1水平与更多免疫细胞浸润呈正相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d201/9208035/586d9c544d99/10.1177_11769351221096655-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验